NeoGenomics (NEO) Stock Forecast & Price Target

NeoGenomics is benefiting from a clear shift toward higher-value NGS and MRD testing, which is lifting both revenue quality and profitability, with Q3 revenue around $209M, NGS up 29%, and ASPs rising to $530 per test. Its margin profile is strengthening as gross margin reached 48.6% and adjusted EBITDA margin expanded to 8.9%, while management raised 2026 revenue guidance to $807M-$809M and EBITDA guidance to about $60M. The outlook is further supported by expanding reimbursement for RaDaR ST and PanTracer LBx, a larger addressable MRD market, and a valuation that remains well below precision oncology peers despite improving execution.

NeoGenomics is facing a negative outlook because private specialty lab rivals are gaining share through better leverage of patient data, more advanced NGS reporting, and aggressive commercial tactics that may displace more of its clinical testing volume than expected. Its profitability profile remains fragile, with the company operating at near breakeven on an Adj. EPS and EBITDA basis, leaving little cushion if surprise Medicare pricing cuts or competitive pressure from new NGS and informatics products further squeeze margins. The company also risks falling behind in precision oncology innovation across tissue, blood, MRD, and early detection testing, while execution concerns around Tempus and volatile pharma ordering patterns add uncertainty to sustained growth.